These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32017367)

  • 1. C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities.
    Yamashita A; Zhang Y; Sanner MF; Griffin JH; Mosnier LO
    J Thromb Haemost; 2020 May; 18(5):1027-1038. PubMed ID: 32017367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An orthosteric/allosteric bivalent peptide agonist comprising covalently linked protease-activated receptor-derived peptides mimics in vitro and in vivo activities of activated protein C.
    Healy LD; Fernández JA; Aiolfi R; Mosnier LO; Griffin JH
    J Thromb Haemost; 2024 Jul; 22(7):2039-2051. PubMed ID: 38670314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.
    Mosnier LO; Yang XV; Griffin JH
    J Biol Chem; 2007 Nov; 282(45):33022-33. PubMed ID: 17872949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46.
    Mosnier LO; Sinha RK; Burnier L; Bouwens EA; Griffin JH
    Blood; 2012 Dec; 120(26):5237-46. PubMed ID: 23149848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.
    Bouwens EA; Stavenuiter F; Mosnier LO
    J Thromb Haemost; 2013 Jun; 11 Suppl 1(0 1):242-53. PubMed ID: 23809128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel protein C-factor VII chimera provides new insights into the structural requirements for cytoprotective protease-activated receptor 1 signaling.
    Gleeson EM; McDonnell CJ; Soule EE; Willis Fox O; Rushe H; Rehill A; Smith OP; O'Donnell JS; Preston RJS
    J Thromb Haemost; 2017 Nov; 15(11):2198-2207. PubMed ID: 28834159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.
    Mosnier LO; Gale AJ; Yegneswaran S; Griffin JH
    Blood; 2004 Sep; 104(6):1740-4. PubMed ID: 15178575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3.
    Burnier L; Mosnier LO
    Blood; 2013 Aug; 122(5):807-16. PubMed ID: 23788139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytoprotective protein C pathway.
    Mosnier LO; Zlokovic BV; Griffin JH
    Blood; 2007 Apr; 109(8):3161-72. PubMed ID: 17110453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1.
    Yang L; Bae JS; Manithody C; Rezaie AR
    J Biol Chem; 2007 Aug; 282(35):25493-500. PubMed ID: 17580306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.
    Mosnier LO; Zampolli A; Kerschen EJ; Schuepbach RA; Banerjee Y; Fernández JA; Yang XV; Riewald M; Weiler H; Ruggeri ZM; Griffin JH
    Blood; 2009 Jun; 113(23):5970-8. PubMed ID: 19244160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.
    Kerschen EJ; Fernandez JA; Cooley BC; Yang XV; Sood R; Mosnier LO; Castellino FJ; Mackman N; Griffin JH; Weiler H
    J Exp Med; 2007 Oct; 204(10):2439-48. PubMed ID: 17893198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell painting with an engineered EPCR to augment the protein C system.
    Bouwens EA; Stavenuiter F; Mosnier LO
    Thromb Haemost; 2015 Nov; 114(6):1144-55. PubMed ID: 26272345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement.
    Harmon S; Preston RJ; Ni Ainle F; Johnson JA; Cunningham MS; Smith OP; White B; O'Donnell JS
    J Biol Chem; 2008 Nov; 283(45):30531-9. PubMed ID: 18779332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated protein C.
    Griffin JH; Fernández JA; Gale AJ; Mosnier LO
    J Thromb Haemost; 2007 Jul; 5 Suppl 1():73-80. PubMed ID: 17635713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C, protease activated receptor 1, and neuroprotection.
    Griffin JH; Zlokovic BV; Mosnier LO
    Blood; 2018 Jul; 132(2):159-169. PubMed ID: 29866816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.
    von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO
    PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated protein C in neuroprotection and malaria.
    Mosnier LO
    Curr Opin Hematol; 2019 Sep; 26(5):320-330. PubMed ID: 31348046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells.
    Yang XV; Banerjee Y; Fernández JA; Deguchi H; Xu X; Mosnier LO; Urbanus RT; de Groot PG; White-Adams TC; McCarty OJ; Griffin JH
    Proc Natl Acad Sci U S A; 2009 Jan; 106(1):274-9. PubMed ID: 19116273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the protein C anticoagulant and antiinflammatory pathways.
    Rezaie AR
    Curr Med Chem; 2010; 17(19):2059-69. PubMed ID: 20423310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.